Inclusion Criteria:

- Histologically or cytologically confirmed advanced solid malignancy

- Patients enrolled in stratum II of the study must have BRCA1/2 mutation (added
04/07/09)

- Patients with CNS metastases must be stable after therapy for CNS metastases (such as
surgery, radiotherapy or stereotactic radiosurgery) for > 3 months and must be off
steroid treatment prior to study enrollment

- ECOG performance status 0-2

- Life expectancy > 12 weeks

- ANC ≥ 1,500/μL

- Platelet count ≥ 100,000/μL

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- AST and ALT ≤ 2.5 times ULN

- Creatinine normal OR creatinine clearance ≥ 60 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for ≥ 3 months after
completion of study treatment

- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

- More than 3 weeks since prior radiotherapy

- Prior veliparib allowed

Exclusion Criteria:

- Known history of allergic reactions to veliparib, carboplatin, or
Cremophor-paclitaxel

- Uncontrolled intercurrent illness, including, but not limited to, any of the
following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness or social situations that would preclude compliance with study
requirements

- Peripheral neuropathy > grade 1

- Inability to take oral medications on a continuous basis

- Active seizure or history of seizure disorder

- Evidence of bleeding diathesis

- Received > 3 prior chemotherapy regimens for advanced stage disease for patients
enrolled in stratum I (there is no upper limit on the number of prior regimens for
patients enrolled in stratum II) (added 04/07/09)

- Adjuvant chemotherapy administered ≥ 2 years prior to enrollment to the study
does not count as a prior chemotherapy regimen

- Other concurrent investigational agents

- Concurrent combination antiretroviral therapy for HIV-positive patients